Correlated Mixed Membership Modeling of Somatic Mutations by Mehta, Rahul & Karaman, Muge
Correlated Mixed Membership Modeling for
Somatic Mutations
Rahul Mehta
Department of Bioengineering
University of Illinois at Chicago
Chicago, IL, USA
mehta5@uic.edu
Muge Karaman
Department of Bioengineering
Center for Magnetic Resonance Research
University of Illinois at Chicago
Chicago, IL, USA
mkaraman@uic.edu
Abstract—Recent studies of cancer somatic mutation profiles
seek to identify mutations for targeted therapy in personalized
medicine. Analysis of profiles, however, is not trivial, as each
profile is heterogeneous and there are multiple confounding
factors that influence the cause-and-effect relationships between
cancer genes such as cancer (sub)type, biological processes,
total number of mutations, and non-linear mutation interactions.
Moreover, cancer is biologically redundant, i.e., distinct mutations
can result in the alteration of similar biological processes, so it is
important to identify all possible combinatorial sets of mutations
for effective patient treatment. To model this phenomena, we
propose the correlated zero-inflated negative binomial process
to infer the inherent structure of somatic mutation profiles
through latent representations. This stochastic process takes
into account different, yet correlated, co-occurring mutations
using profile-specific negative binomial dispersion parameters
that are mixed with a correlated beta-Bernoulli process and
a probability parameter to model profile heterogeneity. These
model parameters are inferred by iterative optimization via
amortized and stochastic variational inference using the Pan
Cancer dataset from The Cancer Genomic Archive (TCGA). By
examining the the latent space, we identify biologically relevant
correlations between somatic mutations.
Index Terms—Bayesian non-parameteric, Somatic Mutations,
mixed-membership modeling
I. INTRODUCTION
Discerning the relationships between somatic mutations in
cancers is the foundation for targeted treatment and patient
subtyping. Since somatic mutations in cancer genomes are
often heterogeneous and sparse, where two patients with the
same cancer may share only one mutation among thousands,
models summarize the high-dimensional interactions into a
simpler form. This requires a model that incorporates multiple
confounding variables to determine relationships between
somatic mutations. Based on current literature [1], [2] mutually
exclusive and co-occurring mutations are influenced by non-
linear relationships between gene mutation frequencies, biolog-
ical processes, cancer (sub)types, total number of mutations
in a tumor (TML), and positive selection for mutations.
The combination of multiple confounding variables and the
inherent sparsity of somatic mutation data poses a challenge to
understand the underlying co-dependencies between mutations.
Statistical and computational models that try to discover
relationships between somatic mutations often decompose a pa-
tient’s mutation profile into a set of higher-level structures that
closely resemble known biological processes. This approach [3],
[4] generally follows a random walk on an existing biological
interaction network. This networks can be modeled as a graph,
G = (V,E), where each vertex, V is a gene, and the edge,
E denotes the interaction among genes. The network is then
modified into a weighted graph, with edge weights representing
probability of interactions and vertex weights corresponding
to the frequency of a mutation in a gene. A walk is then
simulated by starting at a mutated gene and moving to another
gene based on the probabilities of edge and vertex weights. The
end result is a smaller subnetwork called a functional network
that represents an altered biological process. While functional
networks have been validated to discover some aberrant genes
and pathways, they often result in false positives due to the
inherent assumptions made.
The most common compendium of interaction networks
widely used to generate functional networks is the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [5]. The KEGG
interaction networks specify genetic pathways, which are
complex graphical networks with directed and undirected edges
connecting genes based on their physical and biochemical
properties. The genetic pathways are then ascribed to specific
biological processes. For example, the biological process of
cell apoptosis (cell death) is controlled by two known genetic
pathways compromising of a multitude of different genes. The
networks within the KEGG database, however, are diverse
and recapitulate a disease free patient. Functional networks
therefore, assume the interaction networks are also cancer-
relevant and disease-specific. As a result, functional networks
are generalized to a common patient population and struggle
to discriminate between different cancer types [6].
The second assumption is how functional networks take
advantage of mutual exclusivity in somatic mutations. The
process of mutual exclusivity in somatic mutations describes
how mutations do not occur together if they are in the same
genetic pathway [7]. In functional networks, accounting for
mutual exclusivity corresponds to the frequency of a mutation,
which is the weight of a vertex Vi in the graph. Theory, however
suggests that there are multiple confounding factors that cause
mutual exclusivity [1]. For example, the mutual exclusivity of
mutations in the TP53 and MUC16 genes are better explained
by cancer type and TML in cororectal cancer [1].
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The last assumption is of preprocessing somatic mutation
data to a limited number of mutations. Although preprocessing
is done in numerous studies beyond genetics, there is no gold
standard for somatic mutations. Furthermore, due to the high
dimensionalality of somatic mutation data and the limited
number of samples, preprocessing will be biased towards
frequently occurring mutations [8]. So while a model can
identify novel co-occurring mutations within the functional
networks, it may only reflect the model’s preference for a
specific paradigm. For example, HotNet2 [3] removes samples
with more than 400 somatic mutations, however, overdispersion
of a gene and TML are both significant factors that influence
the relationship between mutations.
From a machine learning perspective we can describe the
problems faced by functional networks as overfitting. This is
elucidated by the false positives produced from functional
networks. Specifically, functional networks memorize the
parameters of the interaction network instead of learning
the parameters of the somatic mutation dataset. So while,
functional networks may reproduce valid biological processes,
they do not necessarily capture cancer-relevant relationships
between mutations. For example, functional networks validated
targeted treatment drugs erlotinib or gefitinib for mutations in
the EGFR gene. Since the EGFR is omnipresent in genetic
pathways and as a mutation, functional networks constrain
a patient to be mainly influenced by the EGFR mutation.
From the previous example, these treatments, however, are
only temporarily effective and a relapse often occurs due to
the presence of a co-occurring mutation in the same genetic
pathway that had equal cancerous potential [9]. So, although
functional networks correctly identified the EGFR mutation, it
is the interplay between many mutations that influences cancer
biology.
In this paper, we propose to exploit the inherent latent
structure of a somatic mutation dataset with a generative
probabilistic model. Instead of relying on interaction networks
a priori, we use a prior based on a correlated random measure
(CoRM). The CoRM enables the model to specify a notion of
similarity on the possible latent distributions of the somatic
mutations. In our case, we would like the latent distributions
to correspond to two unique characteristics of the somatic
mutation data: mutual exclusivity and cancer-related biological
processes. Specifically, the CoRM assigns probabilities to
particular configurations of latent distributions via a Zero
Inflated Negative Binomial Process (ZINB) and enforces mutual
exclusivity via a correlation structure through the conjunction
of the Beta-Bernoulli Process and neural networks.
The main contributions of this work are as follows. We
propose the Correlated Zero Inflated Binomial Process, CoZ-
INB, a novel generative latent variable model with an implicit
dependency structure and latent parameters that represent the
sparsity of a somatic mutation dataset. Therefore, CoZINB
avoids biases from frequency and interaction networks that
confound functional network methods. The CoZINB is used
to factorize a somatic mutation profile to infer positively and
negatively correlated latent factors1 that consist of co-occuring
mutations and represent biological processes. We create a
computationally efficient inference scheme with the confluence
of stochastic variational inference and amortized variational
inference [10], [11], [12]. Our experiments on the pan cancer
dataset from The Cancer Genomic Archive (TCGA) verify the
benefits of our model to uncover co-occurring mutations while
maintaining rules of mutual exclusivity and cancer specific
processes.
II. BACKGROUND
A. Negative Binomial Distribution
The dispersion parameter r of the Negative Binomial (NB)
distribution allows models self-excitation [13], an amenable
property in biology, such that if a distinct cancer mutation
occurs in a tumor, it is likely to occur again in the tumor.
Another intuitive way to express the NB distribution is to
model it as a Poisson-Gamma mixture distribution. The NB
distribution is then a weighted mixture of Poisson distributions,
where the rate parameter is an unknown gamma distribution.
Thus, an NB distribution is analogous to an overdispersed
Poisson distribution. Research in differential expression analysis
[14], [15], regression, and clustering of single-cell data [16]
has shown superior performance of NB distribution.
B. Mixed Membership Modeling
Algorithm 1 Latent Dirichlet Allocation a Mixed Membership
Model
for Each cluster k : 1, ...,K do
Sample φk ∼ DirichletM (η1, . . . , ηm)
end for
for Each sample j : 1, ..., J do
Sample θj ∼ DirichletK(α1, . . . , αK)
for Each data point xj ,m in sample j do
Sample Cluster zj,m ∼ DiscreteK(θj)
Sample data point xj,m ∼ DiscreteM (φzj,m)
end for
end for
Mixed-membership modeling is essentially a soft clustering
problem. In contrast to hard clustering where a data point
is assigned to one and only one cluster, each data point in
a mixed-membership model is associated with a number of
clusters. It is the interaction among these clusters that gives
rise to an observed data point. In the context of cancer biology,
mixed-membership models allow us to remove the restrictive
assumption that mutations are mutually exclusive across clusters
[17].
The generative process of LDA follows Algorithm 1. What
specifically matters, is how choosing the priors: the factor score
matrix, θ and the factor loading matrix, φ for different genera-
tive models. For example, if we change the priors in Algorithm
1There are a number of ways to describe sets based on the current
nomenclature (clusters, factors, and topics). For the remainder of the paper
we refer to the latent space of our model as factors.
Sample Gene 1 Gene 2 Gene 3 Gene 4 Gene 5 Gene 6 Gene 7 Gene 8
A 0 1 1 0 1 1 1 0
B 1 1 0 0 1 1 0 0
C 1 1 1 0 0 1 1 0
D 0 1 1 0 0 0 0 0
E 1 1 1 0 1 0 1 1
F 1 0 0 1 0 0 1 0
G 0 1 0 0 1 0 1 0
H 0 1 1 1 1 1 1 1
I 1 1 0 0 0 0 1 0
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A gene mutation influences the development of a cancer type
Cancer type confers the selection of different mutations
The altered biological process influences how frequently a gene is mutated
Mutated genes in turn affect the altered biological process
The altered biological process influences the development of a cancer subtype
In turn the cancer subtype affects the altered biological process
Epigenetic changes affect the progression of cancer (sub)type
The total number of mutations in a tumor represents the evolutionarily pressure of 
multiple variables in cancer progression
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Fig. 1: CoZINB models multiple cofounding variables to determine co-occurring mutations and mutually exclusive mutations. (a)
Is an example of a set of binarized somatic mutation profiles represented as a matrix, where 1 indicates that a gene is mutated
(b-c) There is a complex relationship between cancer, biological processes, and the development of mutations. [1] (d) These
relationships are modeled via a correlated Beta-Bernoulli Process and an independent Gamma process as seen in Equations 2
and 4, where njk is the number of times the kth factor appears in sample j. (e) CoZINB learns a diverse latent structure of
somatic mutation profiles, with positively and negatively correlated factors that contain a set of co-occurring mutations
1 to Gamma distributions and the likelihood to a Poisson
distribution we can obtain Poisson Factor Analysis (PFA)
[13]. Another extension are hierarchical mixed-membership
models, which increase model capability by stacking stochastic
processes such that algorithm infers the number possible
clusters within a dataset [18].
Though powerful, mixed-membership models are limited
as they do not explicitly model the correlations between
the mixing proportions of any two clusters. Using science
articles as an example, the LDA topic model cannot capture
that the presence of a topic on cells is more positively
correlated with a topic on cancer in comparison to a topic on
astronomy. Recent innovations in joint modeling of correlation
and mixture proportions has resulted in improved prediction and
interpretability of the topics as seen in [19] and an hierarchical
extensions in [10], [12], [11]. Continuing in the context of
topic modeling, these methods inject a Gaussian covariance
into the θ such that the factor score matrix takes into account
the correlation between topics. Our model follows this format,
where the bottom stochastic process is based on correlated
random measures.
C. Latent Space as a Correlated Random Measure
Homogenous completely random measure (CRM) [20] is
built upon a mean measure (levy measure) as v(da, dw) =
H(da)vw(dw) where H(da) is the base measure and vw(dw)
is the rate measure. As an example, the Gamma Process
(ΓP) has a mean measure of v(da, dw) = H(da)e−cw/wdw.
Intuitively, we can think of the base measure as defining the
existence of factors and the rate measure assigning a weight
to each factor. This definition allows us to have an infinite
number of factors, but a finite mass, and is a foundation of
many of the non-parametric Bayesian statistical models.
A correlated random measure (CoRM) is created by augment-
ing a CRM into a higher space to include locations such that the
mean measure is now v(da, dw, dl) = H(da)vw(dw)vl(dl),
where vl(dl) is a vector of locations in Rd. We can then
draw correlated weights x via a transformation function
as x ∼ T (·|w,F (l)), given the uncorrelated weights, w,
and a random kernel function on the locations F (l). Based
on Proposition 1 from [11] the transformed levy measure
is now v˜ = v(da, dw, dl)p(dx|F (l), w) The transformation
distribution, like a homogeneous CRM, is restricted to have
finite mass to guarantee generation of useful statistical models.
III. MODEL
A. Correlated Zero Inflated Negative Binomial Process
The Correlated Zero-Inflated Negative Binomial Process
(CoZINB) is a correlated hierarchical Bayesian model for
learning the latent representations of somatic mutation profiles.
We take advantage of neural networks for the random function
F (l) to model non-linear correlations of somatic mutations.
The transformation distribution based on the Beta-Bernoulli
Process (BeBP) is then used to enforce sparsity of the globally
shared latent factors. We describe this is as a draw from the
CoZINB, Xj ∼ NB(RBj , p) with a mean measure v˜:
H(da)vl(dl)αw
−1(1− w)w−1p(dx|F (l), w)R0(dr)dw
so Bj is a draw from the transformation distribution
p(dx|F (l), w) and R is an independent ΓP. By deriving a
latent representation with an unsupervised correlation structure,
we use the inherent information shared across the somatic
mutation profiles to ensure we capture mutual exclusivity
between factors.
As shown in Figure 1, by using CoZINB we can model
1) the excessive amount of mutations that do not occur in
a patient, 2) non-linear interactions of somatic mutations 3)
implicit cancer subtype based on the factors 4) total number of
mutations in a somatic mutation profile. We will show in our
experiments the latent factors follow a pattern of co-occurrence
that is also observed in cancer biology.
B. Generative Structure
We represent our dataset as a bag of words commonly seen
in text corpus, X ∈ NJ×M , where J and M are the number
of patients and distinct number of mutations, respectively. As
in many factor models we also introduce an additional latent
variable, zjm, indicating the factor assignment for mutation m.
The mutation profile of each patient is realized as a mixture
of latent factors (φzjm ) shared by all patients. Specifically, we
model a distinct mutation count in a patient as:
njmk =
Nj∑
i=1
δ(zji = k,mji = m)
njk ∼ NB(rkbjk, pj).
(1)
From a biological perspective njk is the number of times
a k biological process occurs in patient j. The count njmk
corresponds to the contribution of underlying biological process
k to the count of mutation m in sample j. The total number
of mutations in patient j is then Nj . The shape parameter
rk captures the popularity of the biological process k across
all patients. The probability parameter pj models the patient
specific somatic mutation profile. Specifically, pj accounts
for heterogeneity among the patient population. To enable
sparsity and correlations within the latent factors, we introduce
Bernoulli latent variables bjk. When bjk = 1, the latent
factor k is present in patient j, otherwise irrelevant. The
correlations within the binary random variables are produced
via a transformation of the BeBP as discussed in II-C. A
transformed distribution follows [11] as
bjk ∼ Bernoulli(σ(σ−1(pik) + F ()˙))
pik ∼ Beta(α/K,α(1− 1/K))
(2)
where σ is the sigmoid function. As a result, the proposed
model assigns positive probability only to a subset of factors,
based on the correlation structured created in F ()˙.
Inspired by Variational Autoencoders (VAE) [21] to model
nonlinear correlations we use a deep neural network to create
a kernel F ()˙ is:
f(hj , lk) ∼ N(uf (hj , lk), σ2f (hj , lk))
hj ∼ N(0, aI), lk ∼ N(0, bI).
(3)
where hj is a patient specific vector as the output of an
inference network of a VAE. The locations, lk, are then
concatenated with hj as in input the decoder of a VAE to
create the kernel. Unlike the standard VAE decoder which
aims to recreate the input of a encoder, the decoder in our
model supplies prior information to F ()˙. This paradigm of
generating the kernel is similar to Empirical Bayes [22], where
we use the structure of the data as a prior to generate F ()˙.
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Fig. 2: Correlated Zero Inflated Negative Binomial Process
Topic Model
Building upon the above equations, the full generative
structure of the CoZINB topic model follows the paradigm of
the Gamma-Poisson construction of a NB process:
xjm ∼ Discrete(φzjm), zjm,k ∼ φmkθjk
φk ∼ Dirichlet(η01M ), Nj =
K∑
k=1
njk,
njk ∼ Poisson(θjk)θjk ∼ Gamma(rkbjk, pj),
rk ∼ Gamma(γ0, 1/α), γ0 ∼ Gamma(e0, 1/f0),
pj ∼ Beta(a0, b0), Ljk ∼ CRT (njk, rkbjk),
L
′
k ∼ CRT (
J∑
j=1
Ljk, γ0)
(4)
and bjk follows Equation 2. To aid in inference of rk, we
introduce a data augmentation latent variable, Ljk based on
the Chinese Restaurant Table as in [13]. The full model plate
is shown in Figure 2.
C. Inference
Given the set of observed mutation profiles, X and their
corresponding mutation counts m, our goal is to infer the factors
zjm, the factor score matrix, θjk, the factor loading matrix,
φmk, and the factor locations lk. For a biological analogue,
θjk is the proportion of the biological process k in sample j,
φmk is the proportion of each mutation in factor k, and lk is
correlation between a set of co-occurring mutations. Denote
njk =
∑Nj δ(zjm) = k, where K is some finite, but large,
truncation level, we posit the fully factorize variational scheme:
q(θ,φ,pi, Z,R, P, l, L, h) =
K∏
q(lk)q(rk)q(pik)
q(φk)q(γ0)
J∏[
q(hj |X)q(pj)
K∏
q(bjk)q(θjk)q(Ljk)
q(L
′
k)
Nj∏
m=1
q(zjm)
] (5)
The variational distribution for each latent variable is associated
with it’s own variational parameter(s) as follows
q(lk) = δl˜k , q(γ0) = δγ˜0 ,
q(φk) = Dirichlet(η˜)
q(pik) = Beta(τk1, τk2)
q(rk) = Gamma( ˜rk1, ˜rk2)
q(pj) = Beta(a˜j , b˜j)
q(bjk) = Bernoulli(νjk)
q(θjk) = Gamma( ˜θjk1, ˜θjk2)
q(Ljk) = δL˜jk
q(L
′
k) = δ ˜L′k
q(zjm) = Multinomial(ψjm)
We let q(hj |Xj) = δg(Xj) where g is the inference network
of a VAE.
To update the variational parameters we can use stochastic
variational inference (SVI) that assumes we subsample Jt ∈ J
patients at every iteration t and optimize the noisy variational
objective:
Lt = E[ln p(l, r, φ, γ0, pi)]+
J
Jt
∑
j∈Jt
E[lnhj , θj , zj , pj , bj , Lj , Xj ] +H[q(φ]+
J
Jt
∑
j∈Jt
H[q(θj , zj , bj , pj)]
(6)
At each iteration t, we update the local variables, z, θ, b,
and, p using closed form equations, while the remaining
variables, with the exception of φ are updated via stochastic
gradient descent via a decreasing step size [23]. The complete
conditional updates are summarized in Table 1. 2
IV. EXPERIMENTS
To show the importance of modeling sparsity we consider
two latent variable models as comparisons:
PRME is a hierarchical mixed membership model based
on the Dirichlet Process and the correlations are induced
through neural networks with a Gaussian kernel, so θjk ∼
Gamma(rk, f(hj , lk)). Where rk is a stick-breaking Dirichlet
Process instead of a Gamma Process as in CoZINB.
2Note that E[ ˜pik2] = E[pik1](1− pj)E[rk].
Prod-LDA [24] is an extension of LDA to deep generative
models. It replaces the Gaussian Prior in a VAE with a Dirichlet
distributed prior to better learn the latent structure of text data.
To compare CoZINB’s latent factors with functional net-
works, we use the HotNet2 model.
Hotnet2 is used in a discriminate approach to compare
functional networks with CoZINB. We train two distinct
linear support vector machine (SVM) classifiers [25] with
the subnetworks learned by Hotnet2 [3] and the factors from
CoZINB as features. The SVMs are used to predict the cancer
type of a patient given the features. Additionally we compare
the correlation between functional networks and biological
process and the correlation between factors from CoZINB and
biological processes
Architecture encoder and decoder follow simple multilayer
preceptrons (MLP) with dimensions shown in Table II. The
hyperparameters for PRME and CoZINB are set as a = 1, b =
1, α = 1, η = 0.2, a0 = .001, b0 = .001, e0 = .001, f0 = .001,
M = 21332, and a truncation level K as 100 for all models.
All gradient updates are done via Adam [26] with a learning
rate of 1e− 3.
We use the pan cancer dataset from the TCGA consisting of
10296 tumor samples (J) and 21332 distinct mutations (M ).
For training the models we select 70% of the dataset, setting
20% for validation of parameters, and 10% for testing. The
only pre-processing we do is remove ’abParts,’ which is not
represented in any database.
A. Comparison Metrics
Per-heldout-word perplexity
exp(
1
|XTest|
∑
m∈XTest
ln p(Xjm|Xj,Train))
is used to measure the utilization of the latent dimensions of
the two other latent variable models.
Precision@1 measures the influence of the factors on
determining the correct count of one distinct (@1) held-out
mutation as TML increases. This is calculated by
1
N
N∑
1
δ( ˜Xjm = Xjm),
where ˜Xjm is the predict count of mutation m.
Specificity is used to compare the discriminative power
of the functional networks and the latent factors of CoZINB
in predicting the correct cancer type Lung Adenocarcinoma
(LUAD), Colon Cancer (COAD), Ovarianc Cancer (READ),
Stomach Cancer, and Breast Cancer (BRCA).
Spearman-rho is used to assess how well the factors
produced from CoZINB match with biological processes.
Qualitatively we analyze the biological implications of the
factors obtained by CoZINB for a subset of the TCGA dataset
in LUAD and COAD. We chose these subsets as there are
an established number of studies identifying co-occurring and
mutual exclusive somatic mutations within these cancers.
Latent Variable Update Type Variational Update Variational Parameter
φk Closed η +
∑
J∈Jt
∑Nj
n=1 ψjm(k) ∗ 1(Xjm = m˜) ηkm˜
pik Closed α/K +
∑J νjk τk1
pik Closed α(1− 1/K) + J −
∑J νjk τk2
rk Closed γ0 +
∑J E[Ljk] rk1
rk Closed α−
∑J E[bjk] ln 1− pj rk2
pj Closed a0 +Nj a˜
pj Closed b0 +
∑K E [rk]E [bjk] b˜
bjk Closed E[ ˜pik2](E[ ˜pik2] + 1− E[pik1])−1 νjk
θjk Closed E [rk]E
[
bjk
]
+
∑M ψjm(k) ˜θjk1
θjk Closed E [ pj ] ˜θjk2
zjm Closed log θjk + log φkm ψjm
γ0 Gradient Ascent
∑K ∇γ0 E[p(γ0)] +∑J∑K ∇γ0 E [p(L′k|Ljk, γ0)] δγ0
lk Gradient Ascent
∑K ∇l E [ln p(lk)] +∑J∑K ∇l E [p(bjk|pik, hn, lk] δlk
hn Gradient Ascent
∑J ∇h E [ln p(hj)] +∑J∑K ∇h E [p(bjk|pik, hn, lk] δhj
Ljk Gradient Ascent
∑J∑K ∇L E [p(Ljk|njk, bjk, rk] δLjk
TABLE I: A summary of the update information for the Variational Parameters.
V. RESULTS
A. Quantitative
Perplexity@H Encoder Sizes Decoder Sizes
Prod-LDA
@0 1986.30
@100 1091.33
@200 1297.19
@400 1691.76
[M × 100]
[100× 100]
[100× 100]
[100× 100]
[100× 100]
[100×M ]
PRME
@0 1151.96
@100 721.42
@200 997.19
@400 1091.76
[M × 1000]
[1000× 1000]
[1000x1000]
[1000× 40]
[40× 80]
[80× 80]
[80× 80]
[80× 2]
CoZINB
@0 779.69
@100 721.77
@200 699.35
@400 709.34
[M × 1000]
[1000× 1000]
[1000× 1000]
[1000× 40]
[40× 80]
[80× 80]
[80× 80]
[80× 2]
TABLE II: Perplexity of the held-out test Pan Cancer dataset
and architecture of Prod-LDA, PRME, and CoZINB. The @H
indicates if the models were trained with only the top frequently
occurring mutations i.e., @100 is a training set with only top
100 frequently mutations, @0 = no mutations were held out
As Table II shows, CoZINB performs better than PRME
and Prod-LDA when there are a excessive number of zeros
in the dataset. Specifically, we show the importance of using
a prior that can incorporate sparsity, by only using the top
occurring mutations at levels of 100, 200, and 400 during. As
we limit the amount of mutations the models need to learn,
the perplexity of all models begin to improve. The sparsity of
mutations, therefore poses a significant challenge in the learning
paradigm. CoZINB achieved the best performance due to the
use of selector variables bjk. Specifically the selector variables
assigns a finite number of latent factors for each sample and
an explicit zero mass to the rest. Any random signals then
will receive a zero probability, wheres the baseline models will
assign some small probability to the latent factor resulting in
a poor local optima.
In Figure 3 we observe the influence of the CoZINB shape
and probability parameters. The PRME limits the distribution
of the factor score matrix, θjk, to the frequency of latent factors.
In comparison, CoZINB models the count data as the frequency
of the latent factors in rk and the probability of a count of
somatic mutations in pj . More precisely, the expected count of
mutation m in sample j is proportional to pj1−pj and the factor
score matrix.
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Fig. 3: Precision@1 for CoZINB is higher than PRME as
it takes account into the sparsity of the dataset through the
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Our assertion that functional networks via Hotnet2 are not
specific to cancer types and overfit to the structure of interaction
networks is shown in Figure 4. There is a significant variance
in predicting cancer type when using the functional networks,
especially for LUAD. The poor performance for HotNet2 in
LUAD is likely due to the similarities of mutation profiles
of LUAD and LUSC cancers, where LUSC generally has a
higher TML. In contrast, CoZINB factors preserved cancer type
information, especially in BRCA where it achieves an average
specificity of 0.83. This suggests that interaction networks,
while valuable, have much less influence in determining the
relationship between mutations.
In Figure 5 we show the interplay of latent factors in LUAD,
COAD, READ, and BRCA. Each bar represents how many
times a latent factors occurs in a tissue. We can see there
are distinct factors that only correspond to specific cancers.
We use the spearman-rho coefficient to assess if the latent
factors 11, 12, 39, 40, 47, and 52 from BRCA represent
a biological process. We compare it against the spearman-
rho coefficient between functional networks of BRCA and
biological processes. Using the existing database provided by
KEGG, CoZINB has a ρ of 0.67 for the latent factors of
BRCA, while HotNet2 is significantly more correlated with a
ρof 0.78. This not unexpected since HotNet2 is built on the
prior information from interaction networks.
A key insight from Figures 3, 4, and 5 is that we observe
CoZINB’s robust grouping of frequently occurring mutations
into a few factors. The frequently occurring mutations incur a
large penalty due to the ZINB process and the optimization
procedure prevents the probability mass of frequently occurring
mutations to spread across factors. Thereby, the remaining
factors are more diverse and allow for better discriminative
power between TML and cancer type. We see this again in
the case studies below, where frequently occurring mutations
are grouped into Factors 1-4.
B. Lung Adenocarcinoma Case Study
A well studied mutual exclusive set of somatic mutations
in LUAD are KRAS and EGFR. They occur in a significant
fraction of LUAD patients, but are rarely if-ever observed
together in the same tumor. Since these two genes are in the
same pathway and activate similar downstream targets, it is
generally assumed that there is no selective pressure to favor
cells with both mutations over cells with a mutation in one of
them. This behavior is reproduced in CoZINB, where in the
most common factors, KRAS and EGFR are at the opposite
spectrums, with a mean distance of 7185.
The factors that are more unique to LUAD, 5 in our model are
identified by factors 27 with top 5 mutations as: [DNAH5 PCLO
ANK3 TTN TP53BP2] and 37 which include the mutations:
[ USH2A TTN TSHZ2 DNAH3 MUC16]. To confirm this
computationally, we use a simple Random Forest (RF) for
classification of cancer type across all patients using the counts
the top performing factors as features. With a significance of
p < 0.05 RF gives the ranks factors 27 and 37 as the most
important features for LUAD, thereby, verifying our model can
also implicitly determine patient cancer type.
Figure 6 shows the unique factors in every patient with
LUAD as TML increases. Specifically LUAD with high TML
will have some form of the background somatic mutations
captured in factors 0 to 6, however as, TML begins to increase,
occurrences of factors that contain mutually exclusive mutations
will appear. Examining the top underlying somatic mutations
of Factor 30 (MUC16, FLG, LRP1B, ZFHX4 CSMD3, RYR)
and Factor 1 (PIK3CA, PTEN, TP53, MUC16, MAP3K1,), we
observe mutual exclusivity of the MUC15 and TP53 genes as
discussed in section I.
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Fig. 6: A pattern of mutual exclusivity in LUAD. The X-
axis represents a factor, while the Y-axis the total number
of mutations in a tumor. As tumor mutation load increases,
more unique factors appear, specifically ones that are mutually
exclusive with certain somatic mutations.
C. Colon Cancer Case Study
Figure 5 shows Factor 6 is unique to the 408 COAD
tumor samples within the dataset, with top 5 mutations:
[PMVK, BAZ2B, STARD3, SESTD1, KLHL4]. Using the
same methodology as before, a RF classifier ranks factors 6 and
41 as the most significant (p < .05) features for determining if
a patient has Colon Cancer. Moreover, these specific mutations
are also known to commonly occur together as passenger
mutations [27].
COAD also has specific factors associated with increasing
TML in Factors 8 and 21 (p < .01) with mutations: [MUC16,
DNAH5, TTN, PCLO, ANK3] and [BRCA2, CTNNAL1,
DDX52, NAH10, AK9]. Of note are the occurrences of MUC16,
PCLO, and BRCA2, which are all hypermutated in colon
cancers. Similar to LUAD we can see Factor 8 is mutually
exclusive with factors that include the TP53 mutation with
increasing TML.
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Fig. 7: A pattern of mutual exclusivity in COAD. The X-
axis represents a factor, while the Y-axis the total number
of mutations in a tumor. As tumor mutation load increases,
more unique factors appear, specifically ones that are mutually
exclusive with certain somatic mutations.
VI. DISCUSSION AND FUTURE WORK
The CoZINB, unlike existing methods for assessing co-
occurring somatic mutations, is unsupervised and infers a latent
structure in a sparse and complex dataset. A major concept
shown in our model is that we can probabilistically capture
mutual exclusivity between somatic mutations as a non-linear
transformation of multiple latent variables. We also show that
to correctly represent cancer biology and patterns of mutual
exclusivity and co-occurrance in somatic mutations, a model
needs to incorporate tumor mutational load, cancer type, and
non-linear mutation correlations as confounding variables.
Although, we argued against the use of interaction networks,
they might have a place in a semi-supervised framework.
For example, it would be useful to understand the causal
relationship of somatic mutations and unaltered genes, anal-
ogous to link-prediction in community network detection.
This learning paradigm, however, is a complex combinatoral
problem, considering the possible exponential search space of
somatic mutation interactions.
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